Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Line 691: Line 691:
|-
|-
!
!
!
!'''Cytotoxic chemotherapy'''
!
!
|
|
Line 716: Line 716:
|-
|-
!
!
!'''Radiation therapy'''
!
!
!
|Predictable, dose-dependent myelosuppression
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 741: Line 741:
|-
|-
!
!
!
!OTC agents
!
!Quinine-containing beverages
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 790: Line 790:
|-
|-
!
!
! align="center" style="background:#DCDCDC;" + |
! align="center" style="background:#DCDCDC;" + |'''Alcohol'''
!
!
|
|
Line 815: Line 815:
|-
|-
!
!
!
!'''Malignancy'''
!
!
|
|
Line 840: Line 840:
|-
|-
!
!
!
!'''Nutrient deficiencies'''
!
!folate, vitamin B12, copper
|
|an autoimmune mechanism
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Mild
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 865: Line 865:
|-
|-
!
!
!
! rowspan="3" |'''Thrombotic microangiopathy (TMA)'''
!
!Thrombotic thrombocytopenic purpura (TTP)
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 890: Line 890:
|-
|-
!
!
!
!Hemolytic uremic syndrome (HUS)
!
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 915: Line 914:
|-
|-
!
!
!
!Drug-induced TMA (DITMA)
!
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 939: Line 937:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="4" |'''Bone marrow disorders'''
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
!Myelodysplastic syndromes
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!Aplastic anemia
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!Acute leukemia
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!Paroxysmal nocturnal hemoglobinuria (PNH)
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
!
!
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
|}
|}
<references />
<references />

Revision as of 18:20, 7 August 2018

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Category Condition Clinical manifestations Para−clinical findings Gold standard Associated findings
Symptoms Signs
Lab Findings Imaging
Severity Fever Bleeding BP Other CBC PBS Coagulopathy
Mechanism
Infectious diseases Gestational thrombocytopenia
Chronic liver disease
portal hypertension
Hypersplenism
Immune thrombocytopenia Antibody-mediated platelet destruction Moderate to severe - Diagnosis of exclusion
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Category
Infection Viral infections such as:

rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus

HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
Sepsis Direct bone marrow suppression
Helicobacter pylori Immune thrombocytopenia
leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections
Intracellular parasites Malaria
Babesiosis
Medications Drug-induced immune thrombocytopenia
  • Antibiotics
    • Sulfonamides
    • Ampicillin
    • Piperacillin
    • Vancomycin
    • Rifampin
  • Older antiepileptic agents
    • carbamazepine
    • Phenytoin
  • Quinine
Occurrence of drug-dependent, platelet-reactive antibodies
Heparin-induced thrombocytopenia
Cytotoxic chemotherapy
Radiation therapy Predictable, dose-dependent myelosuppression
OTC agents Quinine-containing beverages
Alcohol
Malignancy
Nutrient deficiencies folate, vitamin B12, copper an autoimmune mechanism Mild
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP)
Hemolytic uremic syndrome (HUS)
Drug-induced TMA (DITMA)
Bone marrow disorders Myelodysplastic syndromes
Aplastic anemia
Acute leukemia
Paroxysmal nocturnal hemoglobinuria (PNH)